Cardiology - Global Cardiology Academy

65-80 of 325

Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
AudioAbstracts
Integrating CMR and Genetics to Improve ATTR-CM Diagnosis
Ryan Quigley
- Ryan Quigley
AI-Driven Advances in ATTR-CM Care
AI-Driven Advances in ATTR-CM Care
Heart Matters
AI-Driven Advances in ATTR-CM Care
Frederick Ruberg, MD
- Frederick Ruberg, MD
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Heart Matters
Plasma Biomarkers Associated with HF Hospitalization in Atrial Fibrillation
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
CME/CE
Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
Maria Pabon, MD; Robert J. Mentz, MD, FHFSA, FACC
0.25 credits
- Maria Pabon, MD
- Robert J. Mentz, MD, FHFSA, FACC
0.25 credits
FAI and the Future of Cardiac Risk Stratification
FAI and the Future of Cardiac Risk Stratification
Heart Matters
FAI and the Future of Cardiac Risk Stratification
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Heart Matters
Hidden HFpEF in Atrial Fibrillation: A Missed Diagnosis with Real Consequences
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
On the Frontlines of ATTR-CM
Understanding Vutrisiran’s Cardiac Effects in HELIOS-B
Steve Jackson, PharmD; Karola Jering, MD
- Steve Jackson, PharmD
- Karola Jering, MD
Redefining ATTR-CM Care in the Age of Targeted Therapy
Redefining ATTR-CM Care in the Age of Targeted Therapy
On the Frontlines of ATTR-CM
Redefining ATTR-CM Care in the Age of Targeted Therapy
Steve Jackson, PharmD; David Rind, MD, MSc
- Steve Jackson, PharmD
- David Rind, MD, MSc
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
On the Frontlines of ATTR-CM
RNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
Shelina Ramnarine, PhD; Chadi Alraies, MD, MPH, FACC
- Shelina Ramnarine, PhD
- Chadi Alraies, MD, MPH, FACC
Tracking Disease Progression in ATTR-CM
Tracking Disease Progression in ATTR-CM
On the Frontlines of ATTR-CM
Tracking Disease Progression in ATTR-CM
Ryan Quigley; Joban Vaishnav, MD
- Ryan Quigley
- Joban Vaishnav, MD
Can AI Transform How We Diagnose ATTR-CM?
Can AI Transform How We Diagnose ATTR-CM?
On the Frontlines of ATTR-CM
Can AI Transform How We Diagnose ATTR-CM?
Ryan Quigley; Frederick Ruberg, MD
- Ryan Quigley
- Frederick Ruberg, MD
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
MinuteCE®
GDMT Is Working Fine, Why Add More Therapies? The Clinical Rationale for Layering Therapies in Patients with HFrEF
Javed Butler, MD; Carolyn S. P. Lam, MBBS, PhD
0.75 program credits
- Javed Butler, MD
- Carolyn S. P. Lam, MBBS, PhD
0.75 program credits
MinuteCE®
The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
Javed Butler, MD; Prof. Dr. Johann Bauersachs
0.75 credits 5 episodes
- Javed Butler, MD
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD
0.75 credits 5 episodes
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
CME/CE
GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?
Prof. Dr. Johann Bauersachs; Carolyn S. P. Lam, MBBS, PhD
0.25 credits
- Prof. Dr. Johann Bauersachs
- Carolyn S. P. Lam, MBBS, PhD
0.25 credits
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Ashkan Shoamanesh, MD
- Ashkan Shoamanesh, MD
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Mike Sharma, MD, MSc, FRCPC
- Mike Sharma, MD, MSc, FRCPC

5/10